The National Agency for Food and Drug Administration and Control (NAFDAC) is alerting the public about the distribution and sale of counterfeit Cialis 20mg tablets in Nigeria.
According to Chi Pharmaceutical Ltd, the Marketing Authorization Holder (MAH) for Cialis 20mg film-coated tablets (NRN: 04-5196), the counterfeit version was discovered during a routine market surveillance by field sales representatives of the MAH in Abuja.
It was reported that the counterfeit Cialis 20mg tablets are being sold openly in the market at an average price of ₦8,000 per pack, contrary to the genuine product, which is retailed at about ₦55,000 per pack. Further examination of the counterfeit product showed that it is not consistent with the authentic Cialis 20mg packaging and quality specifications.
Genuine Cialis 20mg Tablet contains tadalafil, which is used to treat erectile dysfunction (ED) in men and pulmonary arterial hypertension (PAH).
Product details
The details of the counterfeit Cialis 20mg tablets versus the genuine ones are as follows.
Product Details | Genuine | Counterfeit |
Product Name | Cialis 20mg film-coated tablets | Cialis Tadalafil tablets 20mg |
Stated NRN | 04-5196 | 4464 |
Manufacturing Date | 03 2023 | 03/2024 |
Expiring Date | 02 2026 | 02/2027 |
Lot. No | D636431 | E3242401 |
Product photo |    |
|
All NAFDAC zonal directors and state coordinators have been directed to carry out surveillance and mop up the counterfeit product within the zones and states.
Importers, distributors, retailers, healthcare professionals, and caregivers are advised to exercise caution and vigilance in the supply chain to prevent the importation, distribution, sale, and use of counterfeit products. All medical products must be obtained from authorized/licensed suppliers. The products’ authenticity and physical condition should be carefully checked.
Healthcare professionals and consumers are advised to report any suspicion of the sale of substandard and falsified medicines or medical devices to the nearest NAFDAC office, NAFDAC on 0800-162-3322, or via email: sf.alert@nafdac.gov.ng
Similarly, healthcare professionals and patients are also encouraged to report adverse events or side effects related to the use of medicinal products or devices to the nearest NAFDAC office, or through the use of the E-reporting platforms available on the NAFDAC website www.nafdac.gov.ng, or via the Med-safety application available for download on Android and IOS stores, or via e-mail on pharmacovigilance@nafdac.gov.ng
Furthermore, note that this notice will be uploaded to the WHO Global Surveillance and Monitoring System (GSMS).
NAFDAC………. Customer-focused, Agency-minded!!!
